1. Home
  2. BCIC vs THAR Comparison

BCIC vs THAR Comparison

Compare BCIC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCIC

BCP Investment Corporation

N/A

Current Price

$12.30

Market Cap

162.3M

Sector

Finance

ML Signal

N/A

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$4.12

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCIC
THAR
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
193.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
BCIC
THAR
Price
$12.30
$4.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
65.1K
1.4M
Earning Date
03-05-2026
03-25-2026
Dividend Yield
15.56%
N/A
EPS Growth
330.32
N/A
EPS
1.64
N/A
Revenue
$58,080,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$14.87
N/A
P/E Ratio
$7.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.12
$0.95
52 Week High
$17.51
$9.08

Technical Indicators

Market Signals
Indicator
BCIC
THAR
Relative Strength Index (RSI) 47.16 56.35
Support Level $12.11 $3.85
Resistance Level $12.38 $5.83
Average True Range (ATR) 0.24 0.53
MACD -0.01 0.06
Stochastic Oscillator 30.77 46.47

Price Performance

Historical Comparison
BCIC
THAR

About BCIC BCP Investment Corporation

BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: